Advertisement

Cocaine

  • Anne P. Daamen
  • Renske Penning
  • Tibor Brunt
  • Joris C. Verster
Chapter

Abstract

After cannabis, cocaine is the most commonly used illicit drug in Europe. An estimated 13 million Europeans have used it at least once in their lifetime. Also, in the USA cocaine is one of the most prevalent illicit drugs, with an annual prevalence of seven million people. Cocaine is a well-known addictive stimulant drug and scientific literature concerning its various pharmacological properties dates back to the nineteenth century. This chapter describes the mechanism of action of cocaine, how addiction and tolerance develop, and the physiological and psychological risks of cocaine use. Finally, pharmacotherapy and psychosocial interventions available to treat cocaine dependence are discussed. It is concluded that none of these interventions have been proven sufficiently effective to reduce craving and maintain abstinence in all patients.

Keywords

Ventral Tegmental Area Posterior Reversible Encephalopathy Syndrome Cocaine Abuse Cocaine User Cocaine Dependence 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Monardes N. Joyfull Newes Out of the Newe Founde Worlde. New York, NY: Alfred Knopf; 1925.Google Scholar
  2. 2.
    Freud S. Uber coca. Centralblad fur die ges. Therapie. 1884;2:289–314.Google Scholar
  3. 3.
    Benson D. Coca kick in drinks spurs export fears. The Washington Times, April 20 2004Google Scholar
  4. 4.
    EM, Editors of Consumer Reports Magazine. The Consumers Union Report on licit and illicit drugs. Consumer Reports Magazine, 1972.Google Scholar
  5. 5.
    Goldstein R, DesLauriers C, Burda A. Cocaine history, social implications and toxicity a review. Dis Mon. 2009;55:6–38.PubMedCrossRefGoogle Scholar
  6. 6.
    Kenyon SL, Ramsey JD, Lee T, Johnston A, Holt DW. Analysis for identification in amnesty bin samples from dance venues. Ther Drug Monit. 2005;27(6):793–8.PubMedCrossRefGoogle Scholar
  7. 7.
    United Nations Office on Drugs and Crime (UNODC). World Drug Report 2008. Vienna: United Nations. http://www.unodc.org/documents/wdr/WDR_2008/WDR_2008_eng_web.pdf.
  8. 8.
    Moffat A. http://clarke.pharm.uu.nl:9876/. Accessed 27 Dec 2008.
  9. 9.
    Hardy J. http://ull.chemistry.uakron.edu/erd/. Accessed 27 Dec 2008.
  10. 10.
    Wishart D. http://www.drugbank.ca/. Accessed 27 Dec 2008.
  11. 11.
    Lexi-comp Online. Lexi-Interact. 1978–2008 Lexi-Comp, Inc. Retrieved June 2008.Google Scholar
  12. 12.
    Liu D, Hariman RJ, Bauman JL. Cocaine concentration-effect relationship in the presence and absence of lidocaine: evidence of competitive binding between cocaine and lidocaine. J Pharmacol Exp Ther. 1996;276(2):568–77.PubMedGoogle Scholar
  13. 13.
    O’Dell L, George FR, Ritz MC. Antidepressant drugs appear to enhance cocaine induced toxicity. Exp Clin Psychpharmacol. 2000;8(1):133–41.CrossRefGoogle Scholar
  14. 14.
    Knuepfer M. Cardiovascular disorders associated with cocaine use: myths and truths. Pharmacol Ther. 2003;97(3):181–222.PubMedCrossRefGoogle Scholar
  15. 15.
    Laizure SC, Mandrell T, Gades NM, et al. Cocaethylene metabolism and interaction with cocaine and ethanol: role of carboxylesterases. Drug Metab Dispos. 2003;31(1):16–20.PubMedCrossRefGoogle Scholar
  16. 16.
    Stahl S (2008) Stahl’s essential psychopharmacology; neuroscientific basis and practical applications, 3rd edition. Cambridge University Press, CambridgeGoogle Scholar
  17. 17.
    Dackis CA, O’Brien CP. Cocaine dependence: a disease of the brain’s reward centers. J Subst Abuse Treat. 2001;21:111–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Filip M, Bubar MJ, Cunningham KA. Contribution of serotonin (5-HT) 5-HT2 receptor subtypes to the hyperlocomotor effects of cocaine: acute and chronic pharmacological analyses. J Pharmacol Exp Ther. 2004;310(3):1246–54.PubMedCrossRefGoogle Scholar
  19. 19.
    Nestler E. The neurobiology of cocaine addiction. Sci Pract Perspect. 2005;3(1):4–10.PubMedCrossRefGoogle Scholar
  20. 20.
    Narendran R, Martinez D. Cocaine abuse and sensitization of striatal dopamine transmission: a critical review of the preclinical and clinical imaging literature. Synapse. 2008;62(11):851–69.PubMedCrossRefGoogle Scholar
  21. 21.
    Steketee JD. Cortical mechanisms of cocaine sensitization. Crit Rev Neurobiol. 2005;17(2):69–86.PubMedCrossRefGoogle Scholar
  22. 22.
    Lu L, Hope BT, Dempsey J, Liu SY, Bossert JM, Shaham Y. Central amygdala ERK signaling pathway is critical to incubation of cocaine craving. Nat Neurosci. 2005;8(2):212–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Li YQ, Li FQ, Wang XY, Wu P, Zhao M, Xu CM, Shaham Y, Lu L. Central amygdala extracellular signal-regulated kinase signaling pathway is critical to incubation of opiate craving. J Neurosci. 2008;28(49):13248–57.PubMedCrossRefGoogle Scholar
  24. 24.
    Fleming JA, Byck R, Barash PG. Pharmacology and therapeutic applications of cocaine. Anesthesiology. 1990;73:518–31.PubMedCrossRefGoogle Scholar
  25. 25.
    Warner EA. Cocaine abuse. Ann Intern Med. 1993;119(3):226–35.PubMedGoogle Scholar
  26. 26.
    Hammer RP, Egilmez Y, Emmett-Oglesby MW. Neural mechanisms of tolerance to the effects of cocaine. Behav Brain Res. 1997;84:225–39.PubMedCrossRefGoogle Scholar
  27. 27.
    Vanderschuren LJ, Everitt BJ. Behavioral and neural mechanisms of compulsive drug seeking. Eur J Pharmacol. 2005;526(1–3):77–88.PubMedCrossRefGoogle Scholar
  28. 28.
    Childress AR, Mozley PD, McElgin W, Fitzgerald J, Reivich M, O’Brien CP. Limbic activation during cue-induced cocaine craving. Am J Psychiatry. 1999;156(1):11–8.PubMedGoogle Scholar
  29. 29.
    Kilts CD, Schweitzer JB, Quinn CK, Gross RE, Faber TL, Muhammad F. Neural activity related to drug craving in cocaine addiction. Arch Gen Psychiatry. 2001;58(4):334–41.PubMedCrossRefGoogle Scholar
  30. 30.
    Volkow ND, Fowler JS, Wang G, Telang F, Logan J, Jayne M, et al. Cognitive control of drug craving inhibits brain reward regions in cocaine abusers. Neuroimage. 2010;49:2536–43.PubMedCrossRefGoogle Scholar
  31. 31.
    Shannon M. Clinical toxicity of cocaine adulterants. Ann Emerg Med. 1988;17(11):1243–7.PubMedCrossRefGoogle Scholar
  32. 32.
    Brunt TM, Rigter S, Hoek J, Vogels N, van Dijk P, Niesink RJ. An analysis of cocaine powder in the Netherlands: content and health hazards due to adulterants. Addiction. 2009;104(5):798–805.PubMedCrossRefGoogle Scholar
  33. 33.
    Koren G, Klein J, Forman R, et al. Hair analysis of cocaine: differentiation between systemic exposure and external contamination. J Clin Pharmacol. 1992;32:671–5.PubMedGoogle Scholar
  34. 34.
    Boghdadi MS, Henning RJ. Cocaine: pathophysiology and clinical toxicology. Heart Lung. 1997;26(6):466–83.PubMedCrossRefGoogle Scholar
  35. 35.
    Chychula NM, Okore C. The cocaine epidemic: a comprehensive review of use, abuse and dependence. Nurse Pract. 1990;15(7):31–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Volkow ND, Wang GJ, Fischman MW, Foltin R, Fowler JS, Franceschi D. Effects of route of administration on cocaine induced dopamine transport blockade in the human brain. Life Sci. 2000;67:1507–15.PubMedCrossRefGoogle Scholar
  37. 37.
    Fattinger K, Benowitz N, Jones R, Verotta D. Nasal mucosal versus gastrointestinal absorption of nasally administered cocaine. Eur J Clin Pharmacol. 2000;56:305–10.PubMedCrossRefGoogle Scholar
  38. 38.
    Cone E. Recent discoveries in pharmacokinetics of drugs of abuse. Toxicol Lett. 1998;102–103:97–101.PubMedCrossRefGoogle Scholar
  39. 39.
    Wilkinson P, van Dyke C, Jatlow P, Barash P, Byck R. Intranasal and oral cocaine kinetics. Clin Pharmacol Ther. 1980;27(3):386–94.PubMedCrossRefGoogle Scholar
  40. 40.
    Cone EJ. Pharmacokinetics and pharmacodynamics of cocaine. J Anal Toxicol. 1995;19:459–78.PubMedGoogle Scholar
  41. 41.
    Hoffman RS. Cocaine. In: Flomenbaum NE, Goldfrank LR, Hoffman RS, et al., editors. Goldfrank’s toxicologic emergencies. 8th ed. New York, NY: McGraw Hill; 2006. p. 1133–46.Google Scholar
  42. 42.
    McCord J, Hani J, Hollander JE. Management of cocaine-associated chest pain and myocardial infarction: a scientific statement from the American Heart Association acute cardiac care committee of the council on clinical cardiology. Circulation. 2008;117(14):1897–907.PubMedCrossRefGoogle Scholar
  43. 43.
    Glauser J, Queen JR. An overview of non-cardiac cocaine toxicity. J Emerg Med. 2007;32(2):181–6.PubMedCrossRefGoogle Scholar
  44. 44.
    Hagan I, Burney K. Radiology of recreational drug abuse. RadioGraphics. 2007;27:919–40.PubMedCrossRefGoogle Scholar
  45. 45.
    Devlin R, Henry J. Clinical review: Major consequences of illicit drug consumption. Crit Care. 2008;12(1):202.PubMedCrossRefGoogle Scholar
  46. 46.
    Restrepo CS, Carrillo JA, Martínez S, Ojeda P, Rivera AL, Hatta A. Pulmonary complications from cocaine and cocaine-based ­substances: imaging manifestations. Radiographics. 2007;27(4):941–56.PubMedCrossRefGoogle Scholar
  47. 47.
    Shanti CM, Lucas CE. Cocaine and the critical care challenge. Crit Care Med. 2003;31(6):1851–9.PubMedCrossRefGoogle Scholar
  48. 48.
    Gitman M, Singhal P. Cocaine-induced renal disease. Expert Opin Drug Saf. 2004;3(5):441–8.PubMedCrossRefGoogle Scholar
  49. 49.
    Linder JD, Monkemuller KE, Raijman I, et al. Cocaine-associated ischemic colitis. South Med J. 2000;93:909–13.PubMedGoogle Scholar
  50. 50.
    Thompson BL, Levitt P, Stanwood G. Prenatal exposure to drugs: effects on brain development and implications for policy and education. Neuroscience. 2009;10(4):303–12.PubMedGoogle Scholar
  51. 51.
    Nnadi CU, Olubansile AM, McCurtis HL, Cadet JL. Neuropsychiatric effects of cocaine use disorders. J Natl Med Assoc. 2005;197(11):1504–15.Google Scholar
  52. 52.
    Rounsaville BJ. Treatment of cocaine dependence and depression. Biol Psychiatry. 2004;56(10):803–9.PubMedCrossRefGoogle Scholar
  53. 53.
    Seibyl JP, Satel SL, Anthony D, Southwick SM, Krystal JH, Charney DS. Effects of cocaine on hospital course in schizophrenia. J Nerv Ment Dis. 1993;181(1):31–7.PubMedCrossRefGoogle Scholar
  54. 54.
    Louwenstein DH, Massa SM, Rowbotham MC, Collins SD, McKinney HE, Simon RP. Acute neurologic and psychiatric complications associated with cocaine abuse. Am J Med. 1987;83:841–6.CrossRefGoogle Scholar
  55. 55.
    Ryb GE, Cooper CC, Dischinger PC, Kufera JA, Auman KM, Soderstrom CA. Suicides, homicides, and unintentional injury deaths after trauma center discharge: cocaine use as a risk factor. J Trauma. 2009;67:409–97.CrossRefGoogle Scholar
  56. 56.
    Jovanovski D, Erb S, Zakzanis KK. Neurocognitive deficits in cocaine users: a quantitative review of evidence. J Clin Exp Neuropsychol. 2005;27:189–204.PubMedCrossRefGoogle Scholar
  57. 57.
    Goldstein RZ, Leskovjan AC, Hoff AL, Hitzemann R, Bashan F, Khalsa SS, et al. Severity of neuropsychological impairment in cocaine and alcohol addiction: association with metabolism in the prefrontal cortex. Neuropsycholgia. 2004;42:1447–58.CrossRefGoogle Scholar
  58. 58.
    Oliveira LG, Barroso LP, Silveira CM, van der Meer Sanchez Z, Ponce JC, Vaz LJ, et al. Neuropsychological assesment of current and past crack cocaine users. Subst Use Misuse. 2009;44:1941–57.PubMedCrossRefGoogle Scholar
  59. 59.
    Ardilla A, Rosselli M, Strumwasser S. Neuropsychological deficits in chronic cocaine abusers. Int J Neurosci. 1991;57:73–9.CrossRefGoogle Scholar
  60. 60.
    Ursitti F, Klein J, Koren G. Confirmation of cocaine use during pregnancy: a critical review. Ther Drug Monit. 2001;23:347–53.PubMedCrossRefGoogle Scholar
  61. 61.
    Meulenbelt J, de Vries I, Joore J. Behandeling van acute vergiftingen, Practische richtlijnen. 1997; Bohn Stafleu Van Loghum.Google Scholar
  62. 62.
    Foltin W, Fischman MW, Pedroso JJ, et al. Marijuana and cocaine interactions in humans: cardiovascular consequences. Pharmacol Biochem Behav. 1987;28(4):459–64.PubMedCrossRefGoogle Scholar
  63. 63.
    Burke WM, Ravi NV, Dhopesh V, et al. Prolonged presence of metabolite in urine after compulsive cocaine use. J Clin Psychiatry. 1990;51(4):145–48.PubMedGoogle Scholar
  64. 64.
    Baselt RC, Baselt DR. Little cross-reactivity of local anesthetics with Abuscreen, EMIT d.a.u., and TDX immunoassays for cocaine metabolite (letter). Clin Chem. 1987;33(5):747.PubMedGoogle Scholar
  65. 65.
    Mikkelsen SL, Ash KO. Adulterants causing false negatives in illicit drug testing. Clin Chem. 1988;34(11):2233–6.Google Scholar
  66. 66.
    Gruszecki AC, Robinson CA, Embry JH, et al. Correlation of the incidence of cocaine and cocaethylene in hair and postmortem biologic samples. Am J Forensic Med Pathol. 2000;21(2):166–71.PubMedCrossRefGoogle Scholar
  67. 67.
    Mazor SS, Mycyk MB, Wills BK, et al. Coca tea consumption causes positive urine cocaine assay. Eur J Emerg Med. 2006;13:340–1.PubMedCrossRefGoogle Scholar
  68. 68.
    Karila L, Gorelick D, Wienstein A, Noble F, Benyamina A, Coscas S, et al. New treatments for cocaine dependence: a focused review. Int J Neuropsychopharmacol. 2008;11:425–38.PubMedCrossRefGoogle Scholar
  69. 69.
    Xi Z-X, Gardner EL. Hypothesis-driven medication discovery for the treatment of psychostimulant addiction. Curr Drug Abuse Rev. 2008;1:303–27.PubMedCrossRefGoogle Scholar
  70. 70.
    Margolin A, Kosten TR, Avants SK, Wilkins J, Ling W, Beckson M. A multicenter trial of bupropion for cocaine dependence in methadone-maintained patients. Drug Alcohol Depend. 1995;40:125–31.PubMedCrossRefGoogle Scholar
  71. 71.
    Shoptaw S, Heinzerling KG, Rotheram-Fuller E, Kao UH, Wang P, Bholat MA, et al. Bupropion hydrochloride versus placebo, in combination with cognitive behavioral therapy, for the treatment of cocaine abuse/dependence. J Addict Dis. 2008;27(1):13–23.PubMedCrossRefGoogle Scholar
  72. 72.
    Mooney ME, Schmitz JM, Moeller FG, Grabowski J. Safety, tolerability and efficacy of levodopa-carbidopa treatment for cocaine dependence: two double-blind randomized, clinical trials. Drug Alcohol Depend. 2007;88:214–23.PubMedCrossRefGoogle Scholar
  73. 73.
    Schmitz J, Mooney M, Moeller F, Stotts A, Green C, Grabowski J. Levodopa pharmacotherapy for cocaine dependence: choosing the optimal behavioral therapy platform. Drug Alcohol Depend. 2008;94(1–3):142–50.PubMedCrossRefGoogle Scholar
  74. 74.
    Preti A. New developments in the pharmacotherapy of cocaine abuse. Addict Biol. 2007;12:133–51.PubMedCrossRefGoogle Scholar
  75. 75.
    de Lima MS, de Oliveira Soares BG, Reisser AA, Farrell M. Pharmacological treatment of cocaine dependence: a systematic review. Addiction. 2002;97(8):931–49.PubMedCrossRefGoogle Scholar
  76. 76.
    Platt DM, Rowlett JK, Spealman RD. Behavioral effects of cocaine and dopaminergic strategies for preclinical medication development. Psychopharmacology (Berl). 2002;163(3–4):265–82.CrossRefGoogle Scholar
  77. 77.
    Dackis CA, Kampman KM, Lynch KG, Pettinati HM, O’Brien CP. A double-blind, placebo controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology. 2005;30:205–11.PubMedCrossRefGoogle Scholar
  78. 78.
    Anderson AL, Reid MS, Li S, Holmes T, Shemanski L, Slee A, Smith EV, et al. Modafinil for the treatment of cocaine dependence. Drug Alcohol Depend. 2009;104:133–9.PubMedCrossRefGoogle Scholar
  79. 79.
    Pani P, Trogu E, Vacca R, Amato L, Vecchi S, Davoli M. Disulfiram for the treatment of cocaine dependence. Cochrane Database Syst Rev. 2010; 20(1):CD007024.Google Scholar
  80. 80.
    Carroll KM, Nich C, Ball SA, McCance E, Rounsaville BJ. Treatment of cocaine and alcohol dependence with psychotherapy and disulfram. Addiction. 1998;93:713–27.PubMedCrossRefGoogle Scholar
  81. 81.
    Carroll KM, Nich C, Ball SA, McCance E, Frankforter TL, Rounsaville BJ. One year follow-up of disulfram and psychotherapy in cocaine-dependent outpatients: a randomized placebo-­controlled trial. Addiction. 2000;95:1335–49.PubMedCrossRefGoogle Scholar
  82. 82.
    Castells X, Casas M, Pérez-Mañá C, Roncero C, Vidal X, Capellà D. Efficacy of psychostimulant drugs for cocaine dependence. Cochrane Database Syst Rev. 2010;(2):CD007380.Google Scholar
  83. 83.
    Haney M, Hart CL, Foltin RW. Effects of baclofen on cocaine self-administration: opioid- and nonopioid-dependent volunteers. Neuropsychpharmacology. 2006;31:1814–21.CrossRefGoogle Scholar
  84. 84.
    Shoptaw S, Yang X, Rotheram-Fuller E, Hsieh Y, Kintaudi P, Charuvastra V, Ling W. Randomized placebo-controlled trial of baclofen for cocaine dependence: preliminary effects for individuals with chronic patterns of cocaine use. J Clin Psychiatry. 2003;64(12):1440–8.PubMedCrossRefGoogle Scholar
  85. 85.
    Brodie J, Figueroa E, Laska E, Dewey S. Safety and efficacy of gamma-vinyl GABA (GVG) for the treatment of methamphetamine and/or cocaine addiction. Synapse. 2005;55(2):122–5.PubMedCrossRefGoogle Scholar
  86. 86.
    Fetchner R, Khouri A, Figueroa E, Ramirez M, Federico M, Dewey SM, et al. Short-treatment of cocaine and/or methamphetamine abuse with vigabatrin: occular safety pilot results. Arch Ophthalmol. 2006;124:1257–62.CrossRefGoogle Scholar
  87. 87.
    Gonzalez G, Desai R, Sofuoglu M, Poling J, Oliveto A, Gonsar K, et al. Tiagebine increases cocaine-free urines in cocaine-dependent methadone treated patients: results of a randomized pilot study. Addiction. 2003;98:1625–32.PubMedCrossRefGoogle Scholar
  88. 88.
    Gonzalez G, Desai R, Sofuoglu M, Poling J, Oliveto A, Gonsai K, et al. Clinical efficacy of gabapentin versus tiagebine for reducing cocaine use among cocaine-dependent methadone treated patients. Drug Alcohol Depend. 2006;87:1–9.PubMedCrossRefGoogle Scholar
  89. 89.
    Winhusen T, Somoza E, Ciraulo DA, Harrer JM, Goldsmtih RJ, Grabowski J. A double-blind placebo controlled trial of tiagabine for the treatment of cocaine dependence. Drug Alcohol Depend. 2007;91:141–8.PubMedCrossRefGoogle Scholar
  90. 90.
    Kampman KM, Pettinati H, Lynch KG, Dackis C, Sparkman T, Weigley C, et al. A pilot trial for the treatment of cocaine dependence. Drug Alcohol Depend. 2004;75:233–40.PubMedCrossRefGoogle Scholar
  91. 91.
    Johnson BA, Roache JD, Ait-Daoud N, Javors MA, Harrison JM, Elkashef A, et al. A preliminary randomized, double-blind, placebo-controlled study of safety and efficacy of ondansetron in the treatment of cocaine dependence. Drug Alcohol Depend. 2006;84:256–63.PubMedCrossRefGoogle Scholar
  92. 92.
    LaRowe SD, Mardikian P, Malcolm R, et al. Safety and tolerability of N-acetylcysteine in cocaine-dependent individuals. Am J Addict. 2006;15:105–10.PubMedCrossRefGoogle Scholar
  93. 93.
    Martell BA, Mitchell E, Poling J, Gonsai K, Kosten TR. Vaccine pharmacotherapy for the treatment of cocaine dependence. Biol Psychiatry. 2005;58(2):158–64.PubMedCrossRefGoogle Scholar
  94. 94.
    Dutra L, Stathopoulou G, Basden SL, Leyro TM, Powers MB, Otto MW. A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry. 2008;165(2):179–87.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Anne P. Daamen
    • 1
  • Renske Penning
    • 1
  • Tibor Brunt
    • 2
  • Joris C. Verster
    • 1
  1. 1.Division of Pharmacology, Utrecht Institute for Pharmaceutical SciencesUtrecht UniversityUtrechtThe Netherlands
  2. 2.Trimbos InstituteUtrechtThe Netherlands

Personalised recommendations